We are live on
!
Find out more
VAM
Visium Asset Management Portfolio holdings
AUM
$1.43B
1-Year Est. Return
3.58%
This Fund
S&P 500
This Quarter
Est. Return
+4.5%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.43B
AUM Growth
-$4.45B
(-76%)
Cap. Flow
-$4.6B
Cap. Flow
% of AUM
-322.21%
Top 10 Holdings %
Top 10 Hldgs %
25.3%
Holding
613
New
146
Increased
30
Reduced
152
Closed
279
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marathon Petroleum
MPC
|
+$24.8M |
| 2 |
KBR
KBR
|
+$24.5M |
| 3 |
MRD
MEMORIAL RESOURCE DEV CORP COM STK (DE)
MRD
|
+$11.4M |
| 4 |
Scorpio Tankers
STNG
|
+$9.89M |
| 5 |
MGIC Investment
MTG
|
+$9.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$280M |
| 2 |
AGN
Allergan plc
AGN
|
+$227M |
| 3 |
ENDP
Endo International plc
ENDP
|
+$138M |
| 4 |
Pacira BioSciences
PCRX
|
+$119M |
| 5 |
Centene
CNC
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 38.43% |
| 2 | Technology | 11.54% |
| 3 | Financials | 10.92% |
| 4 | Energy | 8.32% |
| 5 | Industrials | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVRO
301
DELISTED
NEVRO CORP.
NVRO
| $247K | 0.02% |
3,351
-355,039
| -99% | -$24.1M |
|
|
ARA
302
DELISTED
American Renal Associates Holdings, Inc
ARA
| $243K | 0.02% |
+8,378
| New | +$233K |
|
|
SIOX
303
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $241K | 0.02% |
2,346
-521,750
| -100% | -$52.2M |
|
|
FNHC
304
DELISTED
FedNat Holding Company Common Stock
FNHC
| $240K | 0.02% |
12,617
-30,457
| -71% | -$619K |
|
|
ELGX
305
DELISTED
Endologix Inc
ELGX
| $236K | 0.02% |
1,887
-120,623
| -98% | -$13.9M |
|
|
COE
306
51Talk Online Education Group
COE
$92.2M
| $234K | 0.02% |
+2,950
| New | +$247K |
|
307
Baxter International
BAX
$13.5B
| $233K | 0.02% |
5,149
-683,171
| -99% | -$30M |
|
|
SPNC
308
DELISTED
Spectranetics Corp
SPNC
| $232K | 0.02% |
12,419
-3,580,521
| -100% | -$63.1M |
|
|
SAGE
309
DELISTED
Sage Therapeutics
SAGE
| $223K | 0.02% |
7,395
-1,552,527
| -100% | -$51.8M |
|
310
Neurocrine Biosciences
NBIX
$15.7B
| $219K | 0.02% |
4,837
-1,859,385
| -100% | -$85.6M |
|
311
Waters Corp
WAT
$40.7B
| $218K | 0.02% |
1,559
-48,344
| -97% | -$6.54M |
|
312
Encompass Health
EHC
$11.9B
| $217K | 0.02% |
7,048
-319,281
| -98% | -$9.99M |
|
|
WMGI
313
DELISTED
Wright Medical Group Inc
WMGI
| $215K | 0.02% |
12,416
-1,009,775
| -99% | -$18.5M |
|
|
ITCI
314
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $209K | 0.01% |
5,397
-874,572
| -99% | -$31.4M |
|
|
BPMC
315
DELISTED
Blueprint Medicines
BPMC
| $208K | 0.01% |
10,250
-1,254,775
| -99% | -$22.8M |
|
|
PARA
316
DELISTED
Paramount Global Class B
PARA
| $208K | 0.01% |
3,818
-78,065
| -95% | -$4.24M |
|
|
USCR
317
DELISTED
U S Concrete, Inc.
USCR
| $205K | 0.01% |
+3,357
| New | +$211K |
|
|
GXP
318
DELISTED
Great Plains Energy Incorporated
GXP
| $205K | 0.01% |
6,747
-223,357
| -97% | -$6.86M |
|
319
Minerva Neurosciences
NERV
$231M
| $203K | 0.01% |
+2,482
| New | +$158K |
|
|
ENDP
320
DELISTED
Endo International plc
ENDP
| $188K | 0.01% |
12,063
-6,668,686
| -100% | -$138M |
|
|
ODP
321
CALL
DELISTED
ODP
ODP
| $169K | 0.01% |
5,120
| – | – |
|
322
Akebia Therapeutics
AKBA
$243M
| $161K | 0.01% |
21,526
-1,383,474
| -98% | -$12.1M |
|
323
Insmed
INSM
$25.9B
| $156K | 0.01% |
15,814
-1,567,486
| -99% | -$18.3M |
|
324
Chemours
CC
$2.35B
| $155K | 0.01% |
18,770
-543,696
| -97% | -$4.84M |
|
|
EJ
325
DELISTED
E HOUSE (CHINA) HOLDINGS LIMITED
EJ
| $154K | 0.01% |
+23,806
| New | +$154K |
|
Similar funds
FBNAT
CPS
LH
CPM
VFS
ZA
FVFIGP
WA
Visium Asset Management's Q2 2016 Portfolio in Review
As of Q2 2016, Visium Asset Management held 613 positions worth $1.43B, down 76% from $5.88B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Visium Asset Management withdrew a net $4.6B in Q2 2016, closing 279 positions and reducing 152 holdings. Its most notable exit was Labcorp, an estimated $280M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 38% of assets, up from 7.1% a quarter earlier, followed by Technology and Financials.
Against the trend, Visium Asset Management opened a new position in Marathon Petroleum worth $25.6M.
- Visium Asset Management's largest Q2 2016 buy was Marathon Petroleum: 674,173 shares worth $25.6M.
- Visium Asset Management added most to Nasdaq in Q2 2016, an estimated $7.06M increase.
- Visium Asset Management's biggest Q2 2016 reduction was Allergan plc, cutting an estimated $227M.
- Visium Asset Management fully exited Labcorp in Q2 2016, selling an estimated $280M.
- Visium Asset Management's ten largest holdings make up 25% of its $1.43B portfolio in Q2 2016.
- Visium Asset Management opened 146 new positions and closed 279 in Q2 2016.
- Visium Asset Management's portfolio value fell 76% quarter-over-quarter to $1.43B.
Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.